`
`Phase III Trial of Tocosol Paclitaxel Does Not Meet Primary Endpoint
`
`FDA I EINS
`
`Home
`
`Phase III Trial of Tocosol Paclitaxel Does Not Meet
`
`Primary Endpoint
`
`A Phase III
`in women with metastatic breast cancer did not meet its primary endpoint
`trial of Tocosol Paclitaxel
`of non inferiority on objective response rate when compared with the Taxol control arm Sonus Pharmaceuticals
`reported
`
`The objective response rate for Tocosol Paclitaxel was 37 percent versus 45 percent for Taxol The outcome did
`the submission of a new drug application Sonus added
`not support
`
`The rates of neutropenia and febrile neutropenia in the Tocosol Paclitaxel arm were significantly higher than the
`Taxol arm which may be related to the higher dose of the drug compared with Taxol The study results also did
`in peripheral neuropathy which was not statistically different between the
`not demonstrate the expected benefit
`two arms the company said
`
`Based on these results Sonus and Gennan drugmaker Bayer Schering Pharma said they will close all clinical
`trials of Tocosol Paclitaxel
`
`Copyright ©2017 All Rights Reserved
`FDAnews 300 N Washington St Suite 200 Falls Church VA 22046 USA
`Phone 703 5387600
`Fax 703 5387676
`Toll free 888 8385578
`wwwfdanewscom
`
`httpwwwfdanewscomarticlesprint98911phasei
`
`iitrialoftocosolpacl
`
`itaxeldoesnotmeetprim aryendpoint
`
`11
`
`Abraxis EX2006
`Actavis LLC v Abraxis Bioscience LLC
`1PR201701101 1PR201701103 1PR201701104
`
`